Molecule
Latanoprostene bunod is a prescription medicine indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It is available as eye drops for ophthalmic use. MedsAcross supplies Latanoprostene bunod for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
VYZULTA ® (latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. VYZULTA is a prostaglandin analog indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Source: US FDA prescribing information
Latanoprostene bunod is thought to lower intraocular pressure by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Intraocular pressure is a major modifiable risk factor for glaucoma progression. Reduction of intraocular pressure reduces risk of glaucomatous visual field loss.
Source: US FDA prescribing information
The recommended dosage is one drop in the conjunctival sac of the affected eye(s) once daily in the evening. Do not administer VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% more than once daily since it has been shown that more frequent administration of prostaglandin analogs may lessen the intraocular pressure lowering effect. If VYZULTA is to be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure, administer each drug product at least five minutes apart. One drop in the affected eye(s) once daily in the evening.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Pigmentation: Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent. Eyelash changes: Gradual changes to eyelashes including increased length, increased thickness and number of eyelashes. Usually reversible upon discontinuation of treatment.
Source: US FDA prescribing information
The following adverse reactions are described elsewhere in the labeling: Pigmentation Eyelash Changes Intraocular Inflammation Macular Edema Bacterial Keratitis Use with Contact Lens Most common ocular adverse reactions with incidence ≥ 2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%).
Source: US FDA prescribing information
Unopened bottle should be stored refrigerated at 2°C to 8°C (36°F to 46°F). Once a bottle is opened it may be stored at 2°C to 25°C (36°F to 77°F) for 8 weeks. During shipment, bottles may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 14 days. Protect from freezing. Protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Latanoprostene bunod, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Latanoprostene bunod 0.24 mg/mL eye dropsOphthalmic Cold chainGeneric name | — | US FDA | Available on request |
| Vyzulta 0.24 mg/mL eye dropsOphthalmic Cold chain | Bausch & Lomb | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 2 November 2017 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Latanoprostene bunod in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 2 presentations of Latanoprostene bunod and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Latanoprostene bunod, including Vyzulta.
Yes. The US FDA first approved Latanoprostene bunod on 2 November 2017, according to Drugs@FDA.
At least one listed presentation of Latanoprostene bunod must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.